New York State Psychiatric Institute psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
New York State Psychiatric Institute is listed with 16 registered studies counted here, in New York, United States. By compound: 1 psilocybin and 15 ketamine. By registry status: 1 recruiting, 1 not yet recruiting, 1 active, not recruiting, 10 completed, 2 terminated and 1 suspended. By phase: 5 phase 1, 6 phase 2 and 5 phase 4. Reported start years run from 2009 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 16 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 1 |
| Ketamine | 15 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 6% |
| Not yet recruiting | 1 | 6% |
| Active, not recruiting | 1 | 6% |
| Completed | 10 | 63% |
| Terminated | 2 | 13% |
| Suspended | 1 | 6% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 5 | 31% |
| Phase 2 | 6 | 38% |
| Phase 4 | 5 | 31% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | NCT07139106 | Not yet recruiting | Phase 4 | 2026-02-01 | Ketamine |
| Glutamatergic Mechanisms: Aim2 | NCT05401227 | Recruiting | Phase 1 | 2022-10-15 | Ketamine |
| Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | NCT04656301 | Completed | Phase 2 | 2021-02-26 | Psilocybin |
| IM Ketamine vs Midazolam for Suicidal ER Patients | NCT04640636 | Suspended | Phase 4 | 2021-02-09 | Ketamine |
| Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1) | NCT04589208 | Active, not recruiting | Phase 1 | 2021-01-01 | Ketamine |
| Ketamine Treatment Effects on Synaptic Plasticity in Depression | NCT04091971 | Completed | Phase 4 | 2020-10-09 | Ketamine |
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) | NCT02422290 | Completed | Phase 1 | 2015-03-01 | Ketamine |
| Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD | NCT02206776 | Terminated | Phase 2 | 2014-09-01 | Ketamine |
| Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP) | NCT02062658 | Completed | Phase 2 | 2013-12-01 | Ketamine |
| Ketamine for Suicidality in Bipolar Depression | NCT01944293 | Completed | Phase 1 | 2013-09-01 | Ketamine |
| NMDA Antagonists in Bipolar Depression | NCT01833897 | Completed | Phase 4 | 2013-03-01 | Ketamine |
| Ketamine in the Treatment of Suicidal Depression | NCT01700829 | Completed | Phase 4 | 2012-06-01 | Ketamine |
| The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence | NCT01535937 | Terminated | Phase 1 | 2012-02-01 | Ketamine |
| Glutamatergic Modulation of Cocaine-related Deficits | NCT01790490 | Completed | Phase 2 | 2011-02-01 | Ketamine |
| Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD) | NCT01100255 | Completed | Phase 2 | 2010-04-01 | Ketamine |
| Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder | NCT00956085 | Completed | Phase 2 | 2009-08-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.